AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05805449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Control patients will receive usual standard of care surgical repair of their complex fistula by LIFT or advancement flap technique without any biologic adjunct.
Study NCT05805449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Description: Participants will have 40-50cc of peripheral whole blood drawn into a syringe pre-loaded with acid citrate dextrose (ACD) anticoagulant and concentrated PRP harvested by double centrifugation technique using the manufacturer's kit and benchtop centrifuge. This typically yields 5-8cc of PRP that is 18-times more concentrated than baseline.
Study NCT05805449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Matrix
Description: Participants will receive 200g of paste matrix and 200g injected at the following sites: the internal opening closure site at level of the sphincter muscle, within the walls of the fistula tract along its length, and within the tissue of an advancement flap particularly at areas of tissue apposition.
Study NCT06437756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theraband resistance training
Description: Three sessions of 30 minutes each was used to complete the intervention over the course of six weeks (two sets of 12 repetitions). The participants were warmed up by stretching for 10 minutes before each session Participants were advised to take 5 mins rest before moving to next movement if they would feel fatigued after one movement. Thera-Band was utilized in only three different colors for the workouts.
Study NCT06437756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Resistance Training
Description: The intervention was carried out over the course of six weeks in three sessions of 30 minutes each (two sets of 12 repetitions). The participants were warmed up by stretching for 10 minutes before each session. The resistance-training program was performed with Universal weights.
Study NCT05355155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Biosimilar IBI305
Description: Patients received bevacizumab and FOLFOX4 every two weeks
Study NCT06479902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core stability exercise
Description: Core stability exercises featured moves such as planks and side planks.
Study NCT06479902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Strengthening Exercise
Description: . Diaphragmatic exercises included diaphragmatic breathing in various positions.
Study NCT06129214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prepectoral
Description: Remove all visible synovium in suprapatellar area under distal quadriceps tendon. All other procedures (Total Knee arthroplasty) are same with no intervention arm.
Study NCT06129214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subpectoral
Description: No remove any synovium in suparapatellar area under distal quadriceps tendon. All other preocedures are same with experimental arm.
Study NCT05755126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iatrosedation
Description: Alleviating the anxiety of patients by iatrosedative interview and clinical encounter
Study NCT05755126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical Therapy
Description: Patients were provided with headphones and a playlist to listen to the music of their choice for 10 minutes
Study NCT04992247 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-MSC
Description: 2, 4 or 6 MSC vials (approximately 15 million cells/vial) will be intravenously infused on Day 0, Day 2, or Day 4 depending on assignment to treatment group.~Group A: 2 MSC vials infused on D0 and 2 vials of placebo on D2 and D4~Group B: 2 MSC vials infused on D0 and D2 and 2 vials of placebo on D4~Group C: 2 MSC vials infused on D0 and D4 and 2 vials of placebo on D2~Group D: 2 MSC vials infused on D0, D2 and D4
Study NCT04992247 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 vials of placebo will be intravenously infused on Day 0, Day 2, or Day 4.
Study NCT05475639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Axillary Diclofenac phonophoresis
Description: axillary diclophenac phonophoresis (voltaren gel) will be received three times per week for four weeks
Study NCT05475639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post isometric facilitation
Description: Post isometric facilitation exercise will be received three times per week for four weeks
Study NCT05475639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy
Description: Traditional physiotherapy will be received three times per week for four weeks
Study NCT05989425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib
Description: Surufatinib is a tablet in the form of 50mg, oral, once a day.
Study NCT05545917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: APP care
Description: The experimental arm will receive advanced physiotherapy care (APP) care. Patients will be independently managed (assessment and intervention) by a PT. The PT will make a diagnosis and initiate an intervention plan (e.g. education and exercise). If relevant, the PT will make recommendations for medical imaging tests or medication. PTs will also recommend the proper discharge from the emergency department (ED), such as hospitalization, discharge without medical consultation/follow-up or discharge with a medical follow-up or rehabilitation in an outpatient setting.
Study NCT05545917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control - Usual physician care
Description: The control arm will receive usual ED physician care delivered only by an ED physician. This will include independent assessment, treatment and discharge by an ED physician with no physiotherapy within the ED but physician's referral to outpatient physiotherapy or other professionals/medical specialists will be possible; overall care offered by the ED physician will not be standardized but will be systematically documented.
Study NCT05859698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: Valbenazine capsules for oral administration
Study NCT05150574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Health Program
Description: 8-week structured stress management and health behaviour change program
Study NCT05150574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily resting HRV
Description: Take regular HRV readings in the morning
Study NCT05150574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Momentary HRV feedback
Description: Take regular HRV readings throughout the day when stressed and perform mindfulness activity
Study NCT05150574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural initiation coaching
Description: 15-minute health coaching session in first week of program to help participant set goals and create an action plan
Study NCT05150574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice with feedback coaching
Description: 15-minute health coaching session in week 2 or 4 of program to help participant review goals and modify action plans if needed
Study NCT05362201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic position of the anterior repositioning splints
Description: the ADDWR paricipants will be allocated into 2 grounps and treated with anterior repositioning splints determined by traditional and digitial method respectively.
Study NCT05362201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic position of the anterior repositioning splints
Description: the ADDWR paricipants will be allocated into 2 grounps and treated with anterior repositioning splints determined by traditional and digitial method respectively.
Study NCT05811364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis
Description: Treatment of target lesions in the common and/or external iliac arteries by stenting with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.
Study NCT05811364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent
Description: Treatment of target lesions in the common and/or external iliac arteries by stenting with a commercially available bare metal stent that is approved for treatment of the disease.
Study NCT06235437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASD141
Description: Subjects will receive one of 4 dose levels of ASD141.
Study NCT05158816 — intervention group
Intervention type: PROCEDURE
Intervention: ECMO
Description: Patients undergoing extracorporeal membrane oxygenation
Study NCT06106750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary duct cutting
Description: Endoscopic retrograde cholangiopancreatography and endoscopic nasobiliary duct placement and drainage are conducted first. Upon achieving a postoperative state marked by satisfactory nasobiliary duct drainage and overall patient stability, the procedure entails the employment of endoscopic scissors. The tools are applied to make an incision on the external segment of the nasobiliary duct, positioned beyond the aperture of the primary duodenal papilla. Then extracting the severed nasobiliary duct and retaining the portion inside the duct.
Study NCT06106750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral plastic stent
Description: Standard protocol for the placement of bilateral biliary plastic stents in the management of malignant hilar biliary tract stenosis
Study NCT06386406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAP insole
Description: The patients will have to wear the TAP insole when walking during the everyday life activities.~This plantar insole is not a custom-made insole but a pre-confectioned one because designed according to two parameters: shoe size and gender.
Study NCT05167071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM4003
Description: Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.
Study NCT05167071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Subjects will be treated with Toripalimab on Day 1 during each 21-day cycle.
Study NCT04779177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 42 mg
Description: Lumateperone 42 mg, oral administration
Study NCT04779177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone 28 mg
Description: Lumateperone 28 mg, oral administration
Study NCT04219189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaping condition
Description: Participants will be asked to use a JUUL device to vape 20 puffs over 20 minutes. Participants will use JUUL pods with \~5% nicotine by weight. The anticipated amount of nicotine that will be absorbed with 20 puffs is approximately 1.6 mg, which is equal to approximately 1.5 cigarettes.
Study NCT04219189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control condition
Description: Participants will have access to an uncharged JUUL device with an empty pod for 20 minutes.
Study NCT06265311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IDUS examination
Description: for patients with high risks of bile duct stones recurrence using IDUS during ERCP
Study NCT04730011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short and Intensive Treatment
Description: Intensive Treatment Week with behavioural psychotherapy
Study NCT05534815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Employment-based abstinence reinforcement
Description: Participants will earn stipends for working with the employment specialist and wage supplements for working in a community job, but the stipends and wage supplements will depend on providing drug-free urine samples.
Study NCT06228794 — intervention group
Intervention type: OTHER
Intervention: Peripheral blood test
Description: We will draw 2-5 mL of peripheral blood and utilize multiparameter flow cytometry to measure the level of circulating plasma cells.
Study NCT05093868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrographic Flow Mapping
Description: Electrographic Flow Mapping will be collected
Study NCT05716048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KF-mSMT Plus Aerobic Exercise Training
Description: Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week
Study NCT05716048 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KF-mSMT Plus Stretching Exercise Training
Description: Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week
Study NCT05094427 — intervention group
Intervention type: PROCEDURE
Intervention: Preoperative fluoroscopically-guided dorsal ramus block placed by the operative neurosurgeon
Description: Patients received bupivicaine injections delivered via 22-gauge spinal needle to the junction of the facet and transverse process or ala at multiple spinal levels (2.5-5 cc per injection of 0.25% or 0.5% bupivacaine).
Study NCT05493631 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MG1113
Description: MG1113 subcutaneous (SC) injection
Study NCT06044987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans Obturator Tape Procedure (TOT)
Description: Done under Spinal anesthesia in the dorsal lithotomy position.
Study NCT06044987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans Obturator Tape Procedure (TOT)
Description: Done under Spinal anesthesia in the dorsal lithotomy position.
Study NCT06044987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystocele Repair
Description: Done under Spinal anesthesia in the dorsal lithotomy position..
Study NCT05971589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LM103
Description: Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
Study NCT06572098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex decongestive therapy
Description: Complex decongestive therapy consists of 4 phases. It will be performed by a lymphedema physiotherapist trained in Complex Decongestive Physiotherapy. Complex decongestive therapy consists of manual lymph drainage, skin care, multilayer bandaging and therapeutic exercises.
Study NCT05138562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Description: 4 x placebo capsules, QD
Study NCT05138562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: TU2670 320mg
Description: 320mg (80mg x 4), QD
Study NCT05138562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: TU2670 240mg
Description: 240mg (80mg x 3 + placebo x 1), QD
Study NCT05138562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: TU2670 120mg
Description: 120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD
Study NCT05297682 — intervention group
Intervention type: DEVICE
Intervention: anesthesia with propofol
Description: General anesthesia with propofol
Study NCT05186480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Neo Mune
Description: Neo-mune is a nutritional formula used in enteral feeding for critically ill patients. It's mainly indicated in cases of malnutrition, post surgeries and traumas and immunocompromisation.~Its composition:~Composition in approximate %w/w Maltodextrin 42.44% Sodium caseinate 18.25% MCT oil 6.28% Arginine 5.21% Polydextrose 4.00% Corn oil 3.48% Glutamine 2.61% Fish oil 2.32% Minerals 1.96% Vitamins 0.86% Artificial flavor (vanilla)
Study NCT05604417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAZEMETOSTAT
Description: Dosage and treatment timings per protocol
Study NCT04860297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Sterile liquid for injection
Study NCT05604417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zandelisib
Description: Dosage and treatment timings per protocol
Study NCT05598697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills Building (LSB) curriculum for males
Description: The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All male study participants attending LSB curriculum classes are married to BISP-CT clients.~For men, the MEWE intervention provides access to the LSB curriculum only.
Study NCT05485545 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrophysiological exploration of the right ventricle
Description: * CARTO electrophysiological mapping system~* 3D echocardiography~* High Resolution MRI
Study NCT05598697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills Building (LSB) curriculum for females
Description: The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All female study participants attending LSB curriculum classes are BISP-CT clients.~For females, the MEWE intervention comprises access to LSB curriculum + BISP CTs.
Study NCT05598697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash transfer to adult females
Description: The BISP intervention offers access to quarterly unconditional cash transfers to adult females.
Study NCT05598697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cash transfer to adult females
Description: The BISP intervention offers access to quarterly unconditional cash transfers to adult females.
Study NCT05473845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure intervention
Description: Acupressure
Study NCT05473845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reiki intervention
Description: Reiki
Study NCT05881811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149，probenecid, cimetidine
Description: 40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1\~D4 200mg cimetidine QID from D1\~D4
Study NCT05516303 — intervention group
Intervention type: GENETIC
Intervention: Genetic polymorphism
Description: One blood tube will be taken for genetic testing
Study NCT05516303 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of fingolimod and fingolimod-phosphate concentrations
Description: Measurement of fingolimod and fingolimod-phosphate concentrations before usual drug administration time
Study NCT04836377 — intervention group
Intervention type: OTHER
Intervention: Safety and efficacy assessments
Description: Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention
Study NCT05155176 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intensive Day Monitoring
Description: During intake, a research assistant will demonstrate how to place the HRV monitor, BACtrak Skyn, and provide instructions on completing the saliva samples at home. Participants will wear the HRV and Skyn monitors for three consecutive, randomly selected days twice for individuals with Alcohol Use Disorder and once for social drinkers during the study (72 hours each). Participants will be provided with six saliva sample collection tubes per day with explicit directions on when the saliva sampling should occur (hours since waking: +0, +1, +2, +4, +6, +10 hours, and before going to sleep). Participants will also complete a subjective report using similar questions included in the survey prompts at the same scheduled time as the saliva sample. Individuals with Alcohol Use Disorder would complete a total of 6 such days during the study, and social drinkers would complete a total of 3 such days during the study.
Study NCT04611880 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Crizanlizumab
Description: Drug: crizanlizumab is a humanized monoclonal anti-P-selectin antibody that prevents leukocyte adhesion to the vascular endothelium, thereby limiting risk of microvascular occlusion. It is administered intravenously.
Study NCT05930288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking exercise
Description: The target physical activity level for participants is to walk 10,000 steps per day and to meet or exceed that level (but not exceed 15,000 steps) seven days a week for three to four weeks. Participants will be advised to gradually increase their daily step count in proportion to their physical condition. Exercise will be performed by brisk walking or jogging using the indoor treadmill equipped by the Neurosurgery Department of Xiangya Hospital or outdoors. Each workout will begin with a 5-minute warm-up and end with a 5-minute cool-down.
Study NCT06517992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education for cadre (communicated project)
Description: The investigators perform health education to cadre in order to support their role in providing care for metastatic breast cancer living in the community using a module. The module consists of text (written information) and some videos as education medias.